您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Prosaptide TX14(A)(trifluoroacetate salt)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Prosaptide TX14(A)(trifluoroacetate salt)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Prosaptide TX14(A)(trifluoroacetate salt)图片
包装与价格:
包装价格(元)
500 µg电议
1mg电议
5mg电议
10mg电议

产品介绍
A peptide fragment of prosaposin and GPR37L1 and GPR37 agonist
Canonical SMILESOC(C=C1)=CC=C1C[C@@H](C(O)=O)NC([C@H](CC(C)C)NC([C@H]([C@@H](C)CC)NC([C@H](CCC(O)=O)NC([C@H](CCC(O)=O)NC([C@H]([C@H](O)C)NC([C@H](C)NC([C@H](CC(N)=O)NC([C@H](CC(N)=O)NC([C@H](CC(O)=O)NC([C@H]([C@@H](C)CC)NC([C@H](CC(C)C)NC([C@@H](C)NC([C@@H](N)[C@H](O)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O
分子式C69H110N16O26·XCF3COOH
分子量1579.7
溶解度DMF: 1 mg/ml,DMSO: 1 mg/ml
储存条件-20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Prosaptide TX14(A) is a peptide fragment of the neurotrophic factor prosaposin and an agonist of GPR37L1 and GPR37.1It activates ERK signaling in HEK293T cells expressing GPR37L1 or GPR37 (EC50s = 5 and 7 nM, respectively) and inhibits forskolin-induced cAMP production in the same cells. Prosaptide TX14(A) (100 nM) protects primary mouse astrocytes from hydrogen peroxide-induced cell death. It reduces allodynia in a variety of rat peripheral pain models, including models of diabetic neuropathy and sciatic nerve hemiligation when administered at a dose of 4 mg/kg, as well as prevents paw allodynia induced by formalin at 1 mg/kg.2

1.Meyer, R.C., Giddens, M.M., Schaefer, S.A., et al.GPR37 and GPR37L1 are receptors for the neuroprotective and glioprotective factors prosaptide and prosaposinProc. Natl. Acad. Sci. USA110(23)9529-9534(2013) 2.Jolivalt, C.G., Ramos, K.M., Herbetsson, K., et al.Therapeutic efficacy of prosaposin-derived peptide on different models of allodyniaPain121(1-2)14-21(2006)